Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis

Immunology

Volumn 106, Issue 3, 2002, Pages 428-437

  Cull, Vanessa S ^a   Bartlett, Emmalene J ^a   James, Cassandra M ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL STRAIN COS7; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GENE THERAPY; HEART PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIROGENESIS; VIRUS LOAD; VIRUS MYOCARDITIS; VIRUS REPLICATION; VIRUS TITRATION;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; CYTOKINES; GENE THERAPY; HERPESVIRIDAE INFECTIONS; IMMUNOGLOBULIN G; INTERFERON TYPE I; MALE; MICE; MICE, INBRED BALB C; MUROMEGALOVIRUS; MYOCARDITIS; MYOSINS; TRANSGENES; VIRAL LOAD; VIRUS REPLICATION;

EID: 0036304332     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01423.x     Document Type: Article

References (66)

1. Are all type I human IFNs equivalent?
2. The interferon genes
3. Antiviral actions of IFN. IFN-regulated cellular proteins and their surprisingly selective antiviral activities
4. Characterization of a mouse IFN gene locus, I. Isolation of four IFN genes
5. Segregation of restriction fragment length polymorphism in an interspecies cross of laboratory and wild mice indicates tight linkage of the murine IFN-beta gene to the murine IFN-alpha genes
6. Mapping of murine IFN-α genes to chromosome 4
7. Organisation, structure and expression of murine interferon alpha genes
8. Structure and expression of a new murine IFN-α gene. MuIFN-Alpha 9
9. Mechanisms of viral inhibition by interferons
10. Signaling pathways activated by interferons
11. Biological effects of interferons
12. Virus interference I
13. Effects of hyperthermia on the in vitro antiproliferative activities of HuIFN-α, HuIFN-β, and rHuIFN-γ employed separately and in combination
14. The neglected role of type I interferon in the T-cell response: Implications for its clinical use
15. Induction of bystander T cell proliferation by viruses and type I IFN in vivo
16. In vitro maturation of human neonatal CD4 T lymphocytes. II. Cytokines present at priming modulate the development of lymphokine production
17. + T cells
18. Effects of type I/type II IFNs and transforming growth factor-β on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression
19. Clinical study on long-term hepatitis C with interferon
20. The IFNs. Mechanisms of action and clinical applications
21. Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference
22. Clinical and virological effects of high dose recombinant interferon alpha in disseminated AIDS-related Kaposi's sarcoma
23. Cutaneous tumours: Condyloma acuminatum, basal cell carcinoma, squamous cell carcinoma and melanoma
24. Clinical use of interferons: Hairy cell, chronic myelogenous and other leukemias
25. The role of interferon in the treatment of multiple sclerosis
26. Impact of IFN b-1a on neurologic disability in relapsing multiple sclerosis
27. Cytomegalovirus infections in heart and lung transplant recipients
28. Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using polymerase chain reaction
29. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late stage infection with human immunodeficiency virus
30. Histopathologic profile of human cytomegalovirus infections in patients with heart transplants
31. Cytomegalovirus associated inflammatory heart muscle disease
32. Dilated cardiomyopathy caused by cytomegalovirus infection in a renal transplant recipient
33. Myocarditis - A controversial disease
34. Multiple autoantibodies following cytomegalovirus infection: Virus distribution and specificity of autoantibodies
35. Genetic control of cytomegalovirus induced myocarditis
36. Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin
37. Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity
38. Mouse cyto-megalovirus infection induces antibodies which cross-react with virus and cardiac myosin. A model for the study of molecular mimicry in the pathogenesis of viral myocarditis
39. The role of T cells in mouse cytomegalovirus myocarditis
40. From infection to immunity
41. Characterisation of murine cytomegalovirus myocarditis: Cellular infiltration of the heart and virus persistence
42. In vivo expression of an interferon-α gene by intramuscular injection of naked DNA
43. Anti-viral activities of interferon-α subtypes in vivo
44. Biological activities of recombinant murine interferon alpha 1 and alpha 4: Large difference in antiproliferative effect
45. High efficiency transformation of mammalian cells by plasmid DNA
46. Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice. Enhanced disease severity by impaired inducible nitric oxide synthase induction
47. Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages
48. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus
49. Role of interferon-gamma in murine cytomegalovirus infection
50. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis
51. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: Report of three cases and review
52. Modification of viral myocarditis in mice by interleukin-6
53. Viral myocarditis
54. Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy
55. Cytolytic anticardiac membrane antibodies in the pathogenesis of myopericarditis
56. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in Coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance
57. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice
58. Type I interferons keep activated T cells alive
59. Pancreatic expression of interferon-c protects mice from lethal Coxsackie B3 infection and subsequent myocarditis
60. New structural and functional aspects of the Type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface
61. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
62. Novel vaccine approaches
63. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus
64. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs
65. Gene therapy of rheumatoid arthritis via cytokine regulation: Future perspectives
66. Danger: The view from the bottom of the cliff